1 Braak, H., & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259, doi:10.1007/BF00308809 (1991).
2 Thal, D. R., Rüb, U., Orantes, M., & Braak, H. Phases of Abeta-deposition in the human brain and its relevance for the development of AD. . Neurology 58, 1791-1800, doi:10.1212/WNL.58.12.1791 (2002).
3 Braak, H. & Del Tredici, K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta neuropathologica 121, 171-181 (2011).
4 Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends in pharmacological sciences 12, 383-388 (1991).
5 Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. science 297, 353-356 (2002).
6 Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nature Neuroscience 18, 794-799, doi:10.1038/nn.4017 (2015).
7 Selkoe, D. J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β‐protein. Annals of the New York Academy of Sciences 924, 17-25 (2000).
8 Huang, Y. M., Shen, J., Zhao, H.‐L. . Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease. J Am Geriatr Soc 67, 841-844, doi:https://doi.org/10.1111/jgs.15830 (2019).
9 Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel-Daim, M. M. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease. International journal of molecular sciences 21, 5858, doi:https://doi.org/10.3390/ijms21165858 (2020).
10 Mintun, M. A. et al. Donanemab in Early Alzheimer’s Disease. New England Journal of Medicine 384, 1691-1704, doi:10.1056/NEJMoa2100708 (2021).
11 Honig, L. S. et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med 378, 321-330, doi:10.1056/NEJMoa1705971 (2018).
12 Sperling, R. A., Jack, C. R., Jr. & Aisen, P. S. Testing the right target and right drug at the right stage. Sci Transl Med 3, 111cm133, doi:10.1126/scitranslmed.3002609 (2011).
13 Bloom, G. S. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA neurology 71, 505-508 (2014).
14 Jagust, W. J., Landau, S. M. & Initiative, A. s. D. N. Temporal Dynamics of Beta-amyloid Accumulation in Aging and Alzheimer’s Disease. Neurology (2021).
15 Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. . Staging ß-Amyloid PAthology with Amyloid Positron Emission Tomography. JAMA Neurol. 76, 1319-1329, doi:doi:10.1001/jamaneurol.2019.2214 (2019).
16 Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. . Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications 8, doi:https://doi.org/10.1038/s41467-017-01150-x (2017).
17 Whittington, A., Sharp, D. J., Gunn, R. N., & Alzheimer’s Disease Neuroimaging Initiative. Spatiotemporal Distribution of ß-Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities. The Journal of Nuclear Medicine 59, 822-827, doi:10.2967/jnumed.117.194720 (2018).
18 Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., & Alzheimer's Disease Neuroimaging Initiative In vivo staging of regional amyloid deposition. Neurology 89, 2031-2038, doi:https://doi.org/10.1212/WNL.0000000000004643 (2017).
19 Teipel, S. J., Dyrba, M., Chiesa, P. A., Sakr, F., Jelistratova, I., Lista, S., Vergallo, A., Lemercier, P., Cavedo, E., Habert, M. O., Dubois, B., Hampel, H., Grothe, M. J., & INSIGHT-preAD study group and for the Alzheimerś Disease Neuroimaging Initiative. In-vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer’s disease. Neurobiology of Aging 93, 98-108, doi:https://doi.org/10.1016/j.neurobiolaging.2020.03.011 (2020).
20 Tremblay-Mercier, J. et al. Open Science Datasets from PREVENT-AD, a Longitudinal Cohort of Pre-symptomatic Alzheimer’s Disease. bioRxiv, 2020.2003.2004.976670, doi:10.1101/2020.03.04.976670 (2020).
21 Breitner, J., Poirier, J., Etienne, P. E., & Leoutsakos, J. M. . Rationale and structure for a new center for studies on prevention of Alzheimer’s disease (STOP-AD). J Prev Alzheimers Dis 3, 36–42 (2016).
22 Dagley, A. et al. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage 144, 255-258, doi:10.1016/j.neuroimage.2015.03.069 (2017).
23 Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. . The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. J Clin Exp Neuropsychol 20, 310-319 (1998).
24 Crane, P. K., Carle, A., Gibbons, L. E., Insel, P., Mackin, R. S., Gross, A., Jones, R. N., Mukherjee, S., Curtis, S. M., Harvey, D., Weiner, M., Mungas, D., & Alzheimer’s Disease Neuroimaging Initiative. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav (2012).
25 Gibbons, L. E., Carle, A.C., Macking, R.S., Harvey, D., Mukherjee, S., Insel, P., Curtis, S.M., Gross, A., Jones, R.N., Mungas, D., Weiner, M., & Crane, P.K., for Alzheimer’s Disease Neuroimaging Initiative. Composite measures of executive function and memory: ADNI_EF and ADNI_Mem. (2020).
26 Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimer's & Dementia: Translational Research & Clinical Interventions 3, 668-677, doi:https://doi.org/10.1016/j.trci.2017.10.004 (2017).
27 Miron, J. et al. Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. Alzheimers Dement 15, 951-960, doi:10.1016/j.jalz.2019.03.012 (2019).
28 Meyer, P. F. et al. Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. J Alzheimers Dis 63, 577-590, doi:10.3233/jad-170887 (2018).
29 Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Jr, Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., Heiss, P., Kobold, U., Leinenbach, A., Madin, K., Manuilova, E., Rabe, C., & Blennow, K. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid. Alzheimer's & dementia : the journal of the Alzheimer's Association 12, 517–526, doi:https://doi.org/10.1016/j.jalz.2015.09.009 (2016).
30 Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79, 110-119, doi:10.1002/ana.24546 (2016).
31 Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., Albert, M. S., & Killiany, R. J. . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968-980, doi:10.1016/j.neuroimage.2006.01.021 (2006).
32 Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., Lehmann, M., Rosen, H. J., Reed, B., Olichney, J., Boxer, A. L., Miller, B. L., Borys, E., Jin, L. W., Huang, E. J., Grinberg, L. T., … Jagust, W. . Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 138, 2020-2033, doi:10.1093/brain/awv112 (2015).
33 Baker, S. L., Maass, A., & Jagust, W. J. . Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. Data Brief. 15, 648-657, doi:10.1016/j.dib.2017.10.024 (2017).
34 Clark, C. M., Schneider, J. A., Bedell, B. J., Beach, T. G., Bilker, W. B., Mintun, M. A., Pontecorvo, M. J., Hefti, F., Carpenter, A. P., Flitter, M. L., Krautkramer, M. J., Kung, H. F., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Sabbagh, M. N., Sadowsky, C. H., Reiman, E. P., Zehntner, S. P., Skovronsky, D. M., … AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. . JAMA 305, 275-283, doi:https://doi.org/10.1001/jama.2010.2008 (2011).
35 McSweeney, M., Pichet Binette, A., Meyer, P. F., Gonneaud, J., Bedetti, C., Ozlen, H., Labonté, A., Rosa-Neto, P., Breitner, J., Poirier, J., Villeneuve, S., & PREVENT-AD Research Group Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults. Neurology 94, e1190-e1200, doi:https://doi.org/10.1212/WNL.0000000000008905 (2020).
36 Lee, C. M., Jacobs, H., Marquié, M., Becker, J. A., Andrea, N. V., Jin, D. S., Schultz, A. P., Frosch, M. P., Gómez-Isla, T., Sperling, R. A., & Johnson, K. A. 18F-flortaucipir binding in choroid plexus: related to race and hippocampus signal. Journal of Alzheimer's disease 62, 1691-1702 (2018).
37 Lemoine, L., Leuzy, A., Chiotis, K., Rodriguez-Vieitez, E., & Nordberg, A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 10, 232-236 (2018).
38 Jagust, W. J. et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement 11, 757-771, doi:10.1016/j.jalz.2015.05.001 (2015).
39 Schreiber, S. et al. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. JAMA Neurology 72, 1183-1190, doi:10.1001/jamaneurol.2015.1633 (2015).
40 Buckley, R. F. et al. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11, 670-678, doi:https://doi.org/10.1016/j.dadm.2019.08.004 (2019).
41 Farrell, M. E. et al. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology 96, e619-e631, doi:10.1212/wnl.0000000000011214 (2021).
42 Fantoni, E., Collij, L., Lopes Alves, I., Buckley, C., Farrar, G., & AMYPAD consortium The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. The Journal of Nuclear Medicine 61, 166-171, doi:10.2967/jnumed.119.235879 (2019).
43 Buckley, R. F. et al. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging 78, 178-185, doi:10.1016/j.neurobiolaging.2019.02.019 (2019).
44 Mormino, E. C. et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82, 1760-1767, doi:10.1212/wnl.0000000000000431 (2014).
45 Team, R. C. R: A language and environment for statistical computing. (2013).
46 Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:1406.5823 (2014).
47 Farrell, M. E., Chen, X., Rundle, M. M., Chan, M. Y., Wig, G. S., & Park, D. C. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology 91, e1809-e1821, doi:10.1212/WNL.0000000000006469 (2018).
48 Altman, D. G., & Royston, P. The cost of dichotomising continuous variables. BMJ 332, 1080, doi:10.1136/bmj.332.7549.1080 (2006).
49 Jelistratova, I., Teipel, S. J., & Grothe, M. J. Longitudinal validity of PET-based staging of onal amyloid deposition. Human Brain Mapping, 1-13, doi:DOI: 10.1002/hbm.25121 (2020).
50 Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., Zotova, E., Nicoll, J. A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223, doi:10.1016/s0140-6736(08)61075-2 (2008).
51 Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., Pelidou, S. H. Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines 7, doi:10.3390/biomedicines7040097 (2019).
52 Huber, C. M., Yee, C., May, T., Dhanala, A., Mitchell, C. S. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy. J Alzheimers Dis 61, 265-281, doi:10.3233/jad-170490 (2018).
53 Chen, X. et al. Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. J Neurosci 41, 366-375, doi:10.1523/jneurosci.2111-20.2020 (2021).
54 Knopman, D. S. et al. Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects. Brain 142, 1148-1160, doi:10.1093/brain/awz025 (2019).
55 Hanseeuw, B. J. et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurology 76, 915-924, doi:10.1001/jamaneurol.2019.1424 (2019).
56 Palmqvist, S., Mattsson, N. & Hansson, O. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain 139, 1226-1236, doi:10.1093/brain/aww015 (2016).
57 Mattsson, N. et al. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimers Dement 14, 913-924, doi:10.1016/j.jalz.2018.02.009 (2018).
58 Collij, L. E., Heeman, F., Salvadó, G., Ingala, S., Altomare, D., de Wilde, A., Konijnenberg, E., van Buchem, M., Yaqub, M., Markiewicz, P., Golla, S., Wottschel, V., Wink, A. M., Visser, P. J., Teunissen, C. E., Lammertsma, A. A., Scheltens, P., van der Flier, W. M., Boellaard, R., van Berckel, B., … AMYPAD Consortium. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology 95, e1538-e1553, doi:10.1212/WNL.0000000000010256 (2020).
59 Sakr, F. A., Grothe, M. J., Cavedo, E., Jelistratova, I., Habert, M. O., Dyrba, M., Gonzalez-Escamilla, G., Bertin, H., Locatelli, M., Lehericy, S., Teipel, S., Dubois, B., Hampel, H., INSIGHT-preAD study group, & Alzheimer Precision Medicine Initiative (APMI) Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer’s Resarch & Therapy 11, doi:https://doi.org/10.1186/s13195-019-0466-3 (2019).
60 Leal, S. L., Lockhart, S. N., Maass, A., Bell, R. K., & Jagust, W. J. . Subthreshold Amyloid Predicts Tau Deposition in Aging. The Journal of Neuroscience 38, 4482-4489 (2018).
61 Landau, S. M., Horng, A., Jagust, W. J., & Alzheimer's Disease Neuroimaging Initiative. Memory decline accompanies subthreshold amyloid accumulation. Neurology 90, e1452-e1460, doi:https://doi.org/10.1212/WNL.0000000000005354 (2018).
62 Li, C., Loewenstein, D. A., Duara, R., Cabrerizo, M., Barker, W., Adjouadi, M., & Alzheimer’s Disease Neuroimaging Initiative. The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort. Journal of Alzheimer's disease : JAD 59, 1269–1282, doi:https://doi.org/10.3233/JAD-170286 (2017).
63 Su, Y. et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11, 180-190, doi:https://doi.org/10.1016/j.dadm.2018.12.008 (2019).